UnitedHealthcare NJ (effective March 1, 2026) now classifies embolization of the ovarian or internal iliac veins for Pelvic Congestion Syndrome as unproven and not medically necessary due to insufficient evidence of efficacy. The policy cites mostly low-quality, heterogeneous studies and systematic reviews through 2025 that report symptom improvement but are limited by retrospective designs, small cohorts, inconsistent outcome measures, variable follow-up, and heterogeneous techniques. Recent single-center data suggesting symptom benefit are tempered by concerns about potential harm to ovarian reserve (decreased AMH) and variable recurrence and complication rates. The insurer cites conflicting guideline guidance and calls for randomized, multicenter, longer-term studies before changing coverage.
March 2026 Revision: Noncoverage Determination Declared
What’s new in this March 1, 2026 revision
This UnitedHealthcare New Jersey medical policy, CS139NJ.O, is effective March 1, 2026 and explicitly states a coverage determination: embolization of the ovarian vein or internal iliac vein for Pelvic Congestion Syndrome (PCS) is considered unproven and not medically necessary due to insufficient evidence of efficacy. The document consolidates the payer’s position that current peer-reviewed evidence is low quality and does not establish the relative safety and efficacy of these endovascular interventions.
The revision highlights recent literature through 2025 (including a 2025 single-center retrospective study by Karakaya et al. and systematic reviews through 2024) and reiterates the need for higher-quality randomized controlled trials to change the coverage stance.
Coverage Rationale and Procedural Scope
Coverage rationale and scope for Embolization of the Ovarian Vein and Internal Iliac Vein
The policy’s Coverage Rationale states succinctly that embolization of the ovarian or internal iliac veins for PCS is “unproven and not medically necessary” because of insufficient evidence of efficacy. The declaration applies specifically to the procedural targets named (ovarian vein, internal iliac vein) and the indication Pelvic Congestion Syndrome as defined in the document.
Description and scope language clarifies that embolization techniques under consideration include venography-guided catheterization with placement of embolic agents (metal coils, sclerosing agents, gelatin sponges) to occlude veins and reroute blood flow. The policy notes that embolization is being investigated for individuals who have not adequately responded to conventional treatments.
Clinical Evidence and Limitations Cited
Evidence summary cited in the policy
UnitedHealthcare summarizes a body of mostly low-quality and heterogeneous evidence. The policy cites multiple systematic reviews and cohort studies (e.g., Hanna et al. 2024, Hayes HTA 2020/2023 update, Sutanto et al. 2022, Champaneria et al. 2016, Daniels et al. 2016) that generally report symptom improvement after embolization but are limited by retrospective designs, small series, variable follow-up, and inconsistent outcome measures. Reported technical success rates are high in many series, and some studies report short-term reductions in visual analog scale (VAS) pain scores.
The policy also includes more recent single-center data (Karakaya et al., 2025) noting significant symptom reduction but a concerning decrease in anti-Müllerian hormone (AMH) levels, which raises questions about potential iatrogenic effects on ovarian reserve. Recurrence rates and complication profiles vary across studies; most complications were self-limiting, with rare events such as coil migration.
Guideline Context and Diagnostic Uncertainty
Professional guidelines and interpretive context referenced
The policy references guideline and society positions to contextualize evidence uncertainty. The 2011 Society for Vascular Surgery/American Venous Forum guideline provided a weak (2B) recommendation supporting coil embolization or sclerotherapy for pelvic varices, indicating benefits are balanced with risks. Conversely, the 2020 ACOG practice bulletin on chronic pelvic pain does not address embolization and states that evidence is insufficient to establish a cause-and-effect relationship between pelvic venous congestion and chronic pelvic pain, noting inconsistent diagnostic criteria.
UnitedHealthcare uses these positions to underscore the lack of consensus on diagnosis and standardized protocols; the policy emphasizes the need for robust randomized controlled trials and longer-term, multicenter data to resolve uncertainties about efficacy, durability, and reproductive safety.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.